When the smallpox vaccine first arrived in 19th-century Britain, aristocrats, not peasants, received it first, widening mortality gaps. Aristocrats, no matter how insulated, were one infected servant away from smallpox. Their own self-interest required that vaccination spread outward. Epidemiology created an unexpected moral pressure, where, to protect themselves, the wealthy had to protect everyone. Democracy was not the intention, rather epidemiology coerced it.

Anti-aging science has no equivalent logic. Aging is not contagious. The privileged can age slowly while others age at nature’s pace, and its biology does not force technology to expand outward. Instead, as longevity medicine advances, the result is a technology structurally predisposed to exacerbate inequality unless deliberate interventions like policy and structural reform counterbalance the drift.

I. A World Where the Clock Can Be Rewritten

To make sense of the world emerging around longevity science, I turned to Professor Sheila Jasanoff, whose work on technologies of humility, sociotechnical imaginaries, and anticipatory ethics has shaped how scholars think about the governance of powerful technologies. Her frameworks are useful because longevity research is accelerating quickly, and the imaginative space around it seems to be narrowing just as fast.

Recent years have seen a surge of breakthroughs in longevity science. Around 2014–2015, researchers were able to tangibly grapple with the aspiration of treating aging as a disease. The Targeting Aging with Metformin (TAME) Trial was born as a large clinical study to see whether a cheap, decades-old drug could extend lifespan.

Metformin, though, is only the doorway. In Silicon Valley and the biomedical hubs of Boston, Singapore, and Zurich, longevity research has taken on the fervor of a new technological frontier. The hallmarks of aging, once an academic taxonomy of cellular dysfunctions, have become a blueprint for intervention. Companies are hunting for senolytics, which are drugs that clear out the husks of once-healthy cells that no longer divide and provoke inflammation throughout the body. In principle, it seems intuitive to clean out the clutter with the hopes of rendering tissue young again

Then there is Google’s Calico (née Calico Labs), the anti-aging lab founded in 2013, rumored to have sunk hundreds of millions into basic research partnerships with the Broad Institute down the road in Cambridge among others. Calico rarely speaks publicly, but its existence bears testament to the shifting consensus of aging as a malfunction to be treated rather than a stage in the continuum of human life.

And yet, as Jasanoff noted to me, “People are not talking about anti-aging in the sense of a society that is careful about its history and therefore doesn’t want to change.”* Indeed, scientists have a deeply biological imagination that sees aging largely as biomedical dysfunction. But rippling far beyond its cellular foundations, aging is inextricably linked with the human condition and social scaffolding.*

II. The Coming Inequality of Time

Imagine a society in which some individuals routinely live to 130 or 150 while others inhabit the existing 70–85 year range. The consequences extend far beyond health. Extended life becomes extended earning potential, extended network advantages, extended time to compound wealth. Lifespan then becomes a form of capital.

Today, Americans born into wealthy neighborhoods live up to ten years longer than those in economically disadvantaged ones. But that gap, while unjust, is still anchored in our shared biology. On average, we all age towards the same age ceiling. If longevity science allows a select few to push that ceiling drastically upward, the gap widens from a matter of years to a difference of regimes.

As Jasanoff put it, “If you’re going to have the tech lords of Silicon Valley funding a line of research, they will be interested in the perpetuation of the tech lords.”* In other words, when private money shapes scientific futures, the results tend to reinforce private visions.* If longevity technologies materialize primarily as goods privy to a select few, they risk creating a temporal aristocracy, where select people who inhabit more time thereby accrue more influence. Governance must confront this head-on. Not only is longevity without accessibility therefore simply unequal, it is socially destabilizing.

III. Why Longevity Won’t “Trickle Down” Like Vaccines or Antibiotics

It is tempting to hope that longevity interventions will, like antibiotics or vaccines, trickle down over time. That high initial cost and exclusivity will morph into mass access as patents expire and public campaigns roll out. Yet the biology and political economy of aging resist this precedent

First, aging is not infectious. Like aforementioned, wealthy people face no biological risk if the poor remain excluded. There is no herd-immunity logic pushing toward universality. Moreover, anti-aging therapies often go beyond restoring normal function and instead enhance it. They are not akin to insulin for diabetes but closer to cognitive enhancers or performance boosters. This blurs the line between treatment and augmentation, between medicine as care and medicine as advantage. Are we obliged to offer enhancement, or only to treat preventable suffering?

If biological aging slows, will fertility windows expand? Does motherhood shift into one’s seventies or eighties? Do systems of pensions and insurance collapse under the weight of elongated lives? In sum, what is made clear is that while biology can be optimized in a vacuum, societies cannot.

IV. The Governance Vacuum

Longevity science today is largely governed through what Jasanoff calls a fait accompli approach. This refers to the idea that once scientists make progress, the rest of society simply lags behind, only reacting after the fact. We see this already evident in longevity research, where privately-funded trials take place, and only later do we stop to ask what any of this means for ordinary people. Many believe this order must be reversed. For technologies capable of reshaping something as fundamental as the human lifespan, public participation cannot be an afterthought.*

“Who gets to imagine that good in the first place? Even if you ask somebody what is a good life… you won’t get the same answer from a street sweeper and a Silicon Valley billionaire,” she asserted.*

In India, she explained, scientists hesitate to call something a breakthrough unless it can be deployed as a public health good. Longevity research in the United States does not bear that cultural expectation. Here, innovation is often measured by technical elegance rather than distributional fairness.*

When asked whether agencies like the FDA or WHO could manage longevity’s governance challenges, Jasanoff offered a sober assessment. “They are very limited in their understanding of which representatives they’re willing to tolerate,” she said. But she noted that there are civil society groups, social scientists, among others, that are competent voices.* The challenge is institutional willingness to incorporate them.

V. Can Democracy Survive Immortality?

Modern democratic institutions presuppose mortality and turnover. Indeed, extended life threatens our fundamental assumptions. Lifetime appointments (e.g., Supreme Court Justices) assume mortality. If terms stretch to 150+ years, institutional stasis may intensify. Policies may ossify and younger generations would be immobilized, unable to shape a future dominated by long-lived incumbents

Some scholars argue that mortality itself is a democratic safeguard. Without it, power may stagnate, legitimacy may erode, and the social contract may fracture under the weight of temporal inequality. Hence, longevity interventions, beyond biological risks, may pose existential threats for democratic society

Conclusion

Longevity science, at best, is motivated by a humane impulse to reduce suffering, slow frailty, and give people more healthy years with those they love. There is deep nobility in that aspiration. But technical advances alone cannot guarantee this. Jasanoff’s conception of humility thus entails acknowledging the limits of our predictive capacity and the need for inclusive, value-sensitive deliberation in the face of uncertainty. It is not a tether to halt our innovation. Instead, it asks us to recognize the limits of what we can foresee and to design governance that incorporates a wider range of voices before choices become irreversible.

The question is no longer whether we will extend human life. We already are. The real question is whether we will extend justice alongside it. If we fail to build deliberation, participation, and fairness into longevity science now, we risk creating a world where time itself becomes the most unequal resource of all.

Acknowledgements:

Special thanks to Professor Sheila Jasanoff, whose insight informed these reflections. ​​

* Personal communication (interview) with Professor Sheila Jasanoff, October 2024.